Why the study?
Hypertrophic cardiomyopathy lacks efficacious pharmacologic interventions in the preclinical phase of disease, and novel cardiac myosin inhibitors target actin-myosin interactions to alleviate overactive protein interactions.
Does aficamten alter cardiac function and reduce LVOT pressure gradient in a feline model of obstructive hypertrophic cardiomyopathy?
Does aficamten alter cardiac function and reduce LVOT pressure gradient in a feline model of obstructive hypertrophic cardiomyopathy?
Aficamten demonstrated promising pharmacodynamic effects by reducing LVOT gradients and systolic function in a feline translational model of hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Supports dose exploration in human oHCM trials; leaves open translation from feline model to clinical use.
Sharpe et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: